Why the study?
Syncope in HCM is critical for SCD risk stratification, but causes are often under-investigated or unexplained, and current guidelines lack a detailed definition of unexplained syncope.
How should syncope be diagnosed and managed in patients with hypertrophic cardiomyopathy?
How should syncope be diagnosed and managed in patients with hypertrophic cardiomyopathy?
This expert consensus statement provides practical guidance for the diagnosis and management of syncope in patients with hypertrophic cardiomyopathy, addressing a gap in current guidelines.
Answers are grounded in this paper and cite their sources.
Guides clinicians in evaluating unexplained syncope in HCM; extends SCD risk stratification and fills gaps in existing guidelines.
Syncopal events in patients with hypertrophic cardiomyopathy (HCM) are of concern as they are a vital consideration in algorithms for risk stratification for sudden cardiac death (SCD) and ICD implantation. However, the cause of syncope is often under-investigated and/or unexplained. Current syncope guidelines do not provide a detailed definition of unexplained syncope. To address this important gap, an international panel of experts in the field of both syncope and HCM wrote a consensus document with the aim of providing practical guidance for the diagnosis and management of syncope in patients with HCM.
No takes yet. Share an insight, caveat, or question.
Brignole et al. (2022) conducted a review in Hypertrophic cardiomyopathy with syncope. Diagnostic and management algorithms for syncope was evaluated. An international panel of experts developed a consensus algorithm for the diagnosis and management of unexplained syncope in patients with hypertrophic cardiomyopathy to aid in risk stratification.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: